Physician profile
Robert Lamport
NPI 1750369138
$6,670.98
in general payments reported to CMS, 2019-2025
30 companies · $987 in 2025
The $987 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $977 · 2020: $717 · 2021: $652 · 2022: $1,043 · 2023: $1,118 · 2024: $1,175 · 2025: $987.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,281.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,281.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,502.52 | 2019-2025 | |
| Gilead Sciences, INC. | $1,113.24 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $971.22 | 2019-2025 | Trulance, Plenvu, Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $318.28 | 2019-2025 | Entyvio |
| Pfizer INC. | $286.06 | 2019-2025 | |
| Janssen Biotech, INC. | $233.56 | 2019-2025 | Simponi Aria, Stelara, Simponi |
| Ironwood Pharmaceuticals, INC | $203.65 | 2021-2024 | Linzess |
| Merck Sharp & Dohme LLC | $177.33 | 2023-2024 | Dificid, Zinplava |
| Nestle Healthcare Nutrition INC. | $87.54 | 2020-2022 | |
| Celgene Corporation | $86.76 | 2022-2023 | Zeposia |
| Intercept Pharmaceuticals, INC. | $71.43 | 2019-2023 | Ocaliva |
| Phathom Pharmaceuticals, INC. | $65.99 | 2025 | Voquezna |
| Evoke Pharma, INC. | $58.36 | 2020-2021 | |
| Ardelyx, INC. | $48.67 | 2023-2025 | Ibsrela |
| Intra-Sana Laboratories | $46.60 | 2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $45.99 | 2025 | Terlivaz |
| Daiichi Sankyo INC. | $41.15 | 2021-2025 | Injectafer |
| Vivus LLC | $39.74 | 2022 | |
| Allergan, INC. | $37.22 | 2019-2020 | |
| Dynavax Technologies Corporation | $32.86 | 2021-2022 | |
| Boston Scientific Corporation | $30.35 | 2019 | |
| Lilly USA, LLC | $27.62 | 2024-2025 | Omvoh |
| Madrigal Pharmaceuticals | $27.31 | 2025 | Rezdiffra |
| Novo Nordisk INC | $25.05 | 2025 | Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.08 | 2023 | Cyltezo |
| Medtronic, INC. | $17.84 | 2021 | |
| Redhill Biopharma INC. | $16.41 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $13.53 | 2022 | |
| Ucb, INC. | $11.27 | 2019 | |
| Qol Medical, LLC | $10.35 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Lamport listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.